RA Capital Management 13F holdings, Q4 2013
Holdings as of December 31, 2013 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 24 US equity positions worth $647.8m in its Q4 2013 13F filing. The largest position was ACHILLION PHARMACEUTICALS IN at 12.0% of the reported book, followed by SGMOQ and TXMD. Against the Q3 2013 filing, it opened 7 new positions, added to 7 and reduced 6 among the top 24 holdings.
What did RA Capital Management own in Q4 2013? Top 24 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2013 |
|---|---|---|---|---|---|---|---|
| 1 | ACHILLION PHARMACEUTICALS IN | 12.0% | $77.6m | 23,366,007 | 62% | added | |
| 2 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 11.2% | $72.6m | 5,227,272 | 23% | added |
| 3 | TXMD THERAPEUTICSMD INC | 9.4% | $60.7m | 11,660,108 | -29% | reduced | |
| 4 | NVAX NOVAVAX INC | Healthcare | 8.5% | $55.4m | 10,811,888 | -48% | reduced |
| 5 | OPHTHOTECH CORP | 8.0% | $51.8m | 1,600,455 | – | new | |
| 6 | PROTHENA CORP PLC | 6.7% | $43.5m | 1,641,167 | -0% | held | |
| 7 | DYNAVAX TECHNOLOGIES CORP | 5.4% | $35.1m | 17,883,954 | 198% | added | |
| 8 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 5.1% | $33.0m | 4,347,456 | -26% | reduced |
| 9 | ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 4.5% | $29.2m | 1,169,898 | -43% | reduced |
| 10 | XNCR XENCOR INC | Healthcare | 3.8% | $24.9m | 2,725,000 | – | new |
| 11 | SUNESIS PHARMACEUTICALS INC | 3.6% | $23.1m | 4,869,261 | 0% | held | |
| 12 | ARROWHEAD RESH CORP | 3.4% | $22.2m | 2,049,220 | 133% | added | |
| 13 | DERMA SCIENCES INC | 3.3% | $21.6m | 1,994,876 | 0% | held | |
| 14 | T8S TESARO INC | 3.1% | $19.8m | 700,000 | – | new | |
| 15 | PTCT PTC THERAPEUTICS INC | Healthcare | 2.0% | $12.8m | 752,438 | 151% | added |
| 16 | DYAX CORP | 1.9% | $12.2m | 1,619,697 | -84% | reduced | |
| 17 | MIRATI THERAPEUTICS INC | 1.7% | $10.9m | 656,767 | 19% | added | |
| 18 | BLUEBIRD BIO INC | 1.5% | $9.8m | 467,418 | 0% | held | |
| 19 | OCERA THERAPEUTICS INC | 1.3% | $8.6m | 661,696 | 206% | added | |
| 20 | ENZB ENZO BIOCHEM INC | 1.0% | $6.6m | 2,268,653 | -32% | reduced | |
| 21 | MGNX MACROGENICS INC | Healthcare | 0.8% | $5.5m | 199,398 | – | new |
| 22 | PSIVIDA CORP | 0.7% | $4.7m | 1,187,608 | – | new | |
| 23 | MEI PHARMA INC | 0.5% | $3.3m | 408,333 | – | new | |
| 24 | CHELSEA THERAPEUTICS INTL LT | 0.5% | $3.0m | 666,667 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.